Toll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer

New therapeutic interventions are essential for improved management of patients with metastatic colorectal cancer (mCRC). This is especially critical for those patients whose tumors harbor a mutation in the KRAS oncogene (40-45% of all patients). This patient cohort is excluded from receiving anti-E...

Descripción completa

Detalles Bibliográficos
Autores principales: Maitra, Radhashree, Augustine, Titto, Dayan, Yitzchak, Chandy, Carol, Coffey, Matthew, Goel, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471041/
https://www.ncbi.nlm.nih.gov/pubmed/28422714
http://dx.doi.org/10.18632/oncotarget.16812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471041/
https://www.ncbi.nlm.nih.gov/pubmed/28422714
http://dx.doi.org/10.18632/oncotarget.16812

Ejemplares similares